In a significant regulatory development aimed at controlling substandard imports, the Government of India has imposed price-based import restriction on sulfadiazine API, a key active pharmaceutical ...

The prices for active pharmaceuticals ingredients (API) will recover in FY27 due to the implementation of minimum import price (MIP) starting from 29 January 2026 and China’s withdrawal value-added ...